首页 / 资料库 / 文献详情

眼镜王蛇多肽OH-CATH30可作为潜在候选药物分子杀死临床耐药菌

Feng ZhaoFeng Zhao兰新强Peiyi Chen陈佩仪赵娇Zhao Fang李文辉

2018动物学研究Immunology and Microbiology被引 34开放获取

出版方页面 →

摘要

Cationic antimicrobial peptides (AMPs) are considered as important candidate therapeutic agents, which exert potent microbicidal properties against bacteria, fungi and some viruses. Based on our previous findings king cobra cathelicidin (OH-CATH) is a 34-amino acid peptide that exerts strong antibacterial and weak hemolytic activity. The aim of this research is to evaluate the efficacy of both OH-CATH30 and its analog D-OH-CATH30 against clinical isolates comparing with routinely utilized antibiotics in vitro. In this study, 584 clinical isolates were tested (spanning 2013-2016) and the efficacy of the candidate peptides and antibiotics were determined by a broth microdilution method according to the CLSI guidelines. Among the 584 clinical isolates, 85% were susceptible to OH-CATH30 and its analogs. Both L- and D-OH-CATH30 showed higher efficacy against (toward) Gram-positive bacteria and stronger antibacterial activity against nearly all Gram-negative bacteria tested compare with antibiotics. The highest bactericidal activity was detected against Acinetobacter spp., including multi-drug-resistant Acinetobacter baumannii (MRAB) and methicillin-resistant Staphylococcus aureus (MRSA). The overall efficacy of OH-CATH30 and its analogs was higher than that of the 9 routinely used antibiotics. OH-CATH30 is a promising candidate drug for the treatment of a wide variety of bacterial infections which are resistant to many routinely used antimicrobial agents.

引用本文(GB/T 7714)

Feng Zhao, Feng Zhao, 兰新强, 等. 眼镜王蛇多肽OH-CATH30可作为潜在候选药物分子杀死临床耐药菌[J]. 动物学研究, 2018.

引文网络

参考文献与被引分析加载中…

DOI:https://doi.org/10.24272/j.issn.2095-8137.2018.025

本站仅收录题录与摘要供学习参考,全文版权归属出版方;如有侵权请联系我们删除。